New drugs for the functional cure of hepatitis B: Focusing on antisense oligonucleotides and small interfering RNAs

Xieer LIANG; Zhihong LIU; Jinlin HOU

doi:10.12449/JCH250102

Volume 41 Issue 1

Jan. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(1): 7-14

PDF( 716 KB)

New drugs for the functional cure of hepatitis B: Focusing on antisense oligonucleotides and small interfering RNAs

DOI: 10.12449/JCH250102

Xieer LIANG^{1
,
,
,},
Zhihong LIU¹,
Jinlin HOU^{1, 2}

1.
Department of Infectious Diseases，Nanfang Hospital，Southern Medical University，Guangzhou 510515，China
2.
Guangdong Provincial Institute of Liver Diseases，Guangzhou 510515，China

Research funding:

National Key R & D Program of China (2022YFC2304800);

National Key R & D Program of China (2022YFC2303600)

More Information

Corresponding author: LIANG Xieer， liangxieer@163.com （ORCID： 0000-0002-0862-3291）
Received Date: 2024-11-26
Accepted Date: 2024-12-17
Published Date: 2025-01-25

Abstract

Abstract

Existing nucleos（t）ide analogues and pegylated interferon exhibit limited efficacy in the functional cure of hepatitis B. Recently， small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， have brought unprecedented breakthroughs in the functional cure of hepatitis B with their brand-new mechanisms of action and remarkable efficacy in early clinical studies. Small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， can reduce the level of HBsAg and strive to achieve HBsAg seroclearance. The reduction in HBsAg may restore the hepatitis B-specific immune function of the body to some extent and may further transform the simple clearance of HBsAg into hard endpoints with clinical value， such as reducing hepatitis B-related liver events. By meticulously analyzing the dynamic trajectory of HBsAg alterations within the context of new drug applications and further optimizing combined treatment strategies and regimens， it is expected to transform the functional cure of hepatitis B into the ultimate goal of improving survival rates and quality of life.
- Hepatitis B,
- Oligonucleotides， Antisense,
- RNA， Small Interfering,
- Hepatitis B Surface Antigens,
- Functional Cure

FullText(HTML)

References(42)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
[2]	European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
[3]	TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560- 1599. DOI: 10.1002/hep.29800.
[4]	FELD JJ, LOK AS, ZOULIM F. New perspectives on development of curative strategies for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2023, 21( 8): 2040- 2050. DOI: 10.1016/j.cgh.2023.02.032.
[5]	FANNING GC, ZOULIM F, HOU JL, et al. Therapeutic strategies for hepatitis B virus infection: Towards a cure[J]. Nat Rev Drug Discov, 2019, 18( 11): 827- 844. DOI: 10.1038/s41573-019-0037-0.
[6]	KIM GA, LIM YS, HAN S, et al. Viral load-based prediction of hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B: A multinational study for the development and external validation of a new prognostic model[J]. Ann Intern Med, 2024, 177( 10): 1308- 1318. DOI: 10.7326/M24-0384.
[7]	FAN R, PAPATHEODORIDIS G, SUN J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73( 6): 1368- 1378. DOI: 10.1016/j.jhep.2020.07.025.
[8]	YIP TCF, WONG GLH, CHAN HLY, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues[J]. J Hepatol, 2019, 70( 3): 361- 370. DOI: 10.1016/j.jhep.2018.10.014.
[9]	YIP TCF, LOK ASF. How do we determine whether a functional cure for HBV infection has been achieved?[J]. Clin Gastroenterol Hepatol, 2020, 18( 3): 548- 550. DOI: 10.1016/j.cgh.2019.08.033.
[10]	GHANY MG, BUTI M, LAMPERTICO P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference[J]. Hepatology, 2023, 78( 5): 1654- 1673. DOI: 10.1097/HEP.0000000000000431.
[11]	U. S. Food and Drug Administration. Chronic hepatitis B virus infection: developing drugs for treatment guidance for industry[EB/OL].( 2022-04-07)[ 2024-09-02]. https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/chronic-hepatitis-bvirus-infection-developing-drugs-treatment. https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/chronic-hepatitis-bvirus-infection-developing-drugs-treatment
[12]	National Drug Administration Drug Evaluation Center. Technical guidelines for clinical trials of antiviral drugs for chronic hepatitis B[EB/OL].( 2024-04-27)[ 2024-09-02]. https://www.cde.org.cn/main/news/viewinfocommon/5bebddb98aae85a980181683a910788e. https://www.cde.org.cn/main/news/viewinfocommon/5bebddb98aae85a980181683a910788e 国家药品监督管理局药品审评中心. 慢性乙型肝炎抗病毒治疗药物临床试验技术指导原则[EB/OL].( 2024-04-27)[ 2024-09-02]. https://www.cde.org.cn/main/news/viewinfocommon/5bebddb98aae85a980181683a910788e. https://www.cde.org.cn/main/news/viewinfocommon/5bebddb98aae85a980181683a910788e
[13]	MIAO YX, FU C, YU ZJ, et al. Current status and trends in small nucleic acid drug development: Leading the future[J]. Acta Pharm Sin B, 2024, 14( 9): 3802- 3817. DOI: 10.1016/j.apsb.2024.05.008.
[14]	YUEN MF, HEO J, JANG JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: A phase 2 randomized controlled trial[J]. Nat Med, 2021, 27( 10): 1725- 1734. DOI: 10.1038/s41591-021-01513-4.
[15]	GANE EJ, KIM W, LIM TH, et al. First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection[J]. J Hepatol, 2023, 79( 5): 1139- 1149. DOI: 10.1016/j.jhep.2023.07.026.
[16]	HOU JL, ZHANG WH, XIE Q, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B[J]. N Engl J Med, 2024, 391( 22): 2098- 2109. DOI: 10.1056/nejmoa2405485.
[17]	FAN R, ZHAO SR, NIU JQ, et al. High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy[J]. Gut, 2024, 73( 10): 1725- 1736. DOI: 10.1136/gutjnl-2024-332182.
[18]	YUEN MF, LIM SG, PLESNIAK R, et al. Efficacy and safety of bepirovirsen in chronic hepatitis B infection[J]. N Engl J Med, 2022, 387( 21): 1957- 1968. DOI: 10.1056/NEJMoa2210027.
[19]	BUTI M, HEO J, TANAKA Y, et al. Sequential PEG-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B[J]. J Hepatol, 2025, 82( 2): 222- 234. DOI: 10.1016/j.jhep.2024.08.010.
[20]	DOUCETTE K, JELEV D, KAO J. Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the piranga phase 2, randomized, controlled, adaptive, open-label platform study[C]. AASLD the Liver Meeting, 2024, Abstract 5043.
[21]	GANE E, LIM YS, KIM JB, et al. Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials[J]. J Hepatol, 2023, 79( 4): 924- 932. DOI: 10.1016/j.jhep.2023.05.023.
[22]	YUEN MF, LIM YS, YOON KT, et al. VIR-2218(elebsiran) plus pegylated interferon-Alfa-2a in participants with chronic hepatitis B virus infection: A phase 2 study[J]. Lancet Gastroenterol Hepatol, 2024, 9( 12): 1121- 1132. DOI: 10.1016/S2468-1253(24)00237-1.
[23]	JANSSEN HLA, HOU JL, ASSELAH T, et al. Randomised phase 2 study(JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection[J]. Gut, 2023, 72( 7): 1385- 1398. DOI: 10.1136/gutjnl-2022-328041.
[24]	VENDEVILLE S, AMBLARD F, BASSIT L, et al. The discovery and preclinical profile of ALG-000184, a prodrug of the potent hepatitis B virus capsid assembly modulator ALG-001075[J]. J Med Chem, 2024, 67( 23): 21126- 21142. DOI: 10.1021/acs.jmedchem.4c01814.
[25]	THI EP, YE X, SNEAD NM, et al. Control of hepatitis B virus with imdusiran, a small interfering RNA therapeutic[J]. ACS Infect Dis, 2024, 10( 10): 3640- 3649. DOI: 10.1021/acsinfecdis.4c00514.
[26]	YUEN MF, LOCARNINI S, LIM TH, et al. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB[J]. J Hepatol, 2022, 77( 5): 1287- 1298. DOI: 10.1016/j.jhep.2022.07.010.
[27]	GEORGE J, STEFANOVA-PETROVA D, ANTONOV K. Evaluation of the Vebicorvir, NrtI and AB-729 combination in virologically suppressed patients with HBeAg negative chronic hepatitis B virus infection: interim analysis from an open label phase 2 study[C]. AASLD the Liver Meeting, 2022, Abstract 5064.
[28]	YUEN MF, ASSELAH T, JACOBSON IM, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379(bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection(REEF-1): A multicentre, double-blind, active-controlled, randomised, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8( 9): 790- 802. DOI: 10.1016/S2468-1253(23)00148-6.
[29]	DONG S, WANG Z. Robust hepatitis B surface antigen reduction by ht-101 in chronic hepatitis B patients: results from a phase Ib study[J]. AASLD the Liver Meeting, 2024, Abstract 5012.
[30]	DING Y, YU X, LIANG X. HBsAg loss and seroconversion in HBeAg-negative chronic hepatitis B subjects on na therapy after AHB-137 treatment: preliminary data from an ongoing multicenter, randomized, open-label phase IIa study[J]. AASLD the Liver Meeting, 2024, Abstract 5011.
[31]	AGARWAL K, BUTI M, van BÖMMEL F, et al. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2[J]. J Hepatol, 2024, 81( 3): 404- 414. DOI: 10.1016/j.jhep.2024.03.046.
[32]	CORNBERG M, LOK ASF, TERRAULT NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B-Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference[J]. J Hepatol, 2020, 72( 3): 539- 557. DOI: 10.1016/j.jhep.2019.11.003.
[33]	MAK LY, WOODDELL CI, LENZ O, et al. Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989[J]. Gut, 2024: gutjnl-gu2024- 333026. DOI: 10.1136/gutjnl-2024-333026.
[34]	YUEN MF, WONG DKH, SCHLUEP T, et al. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment[J]. Gut, 2022, 71( 4): 789- 797. DOI: 10.1136/gutjnl-2020-323445.
[35]	TOUT I, LOUREIRO D, MANSOURI A, et al. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development[J]. J Hepatol, 2020, 73( 2): 409- 422. DOI: 10.1016/j.jhep.2020.04.013.
[36]	HIRODE G, CHOI HSJ, CHEN CH, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multicenter, multiethnic cohort(RETRACT-B study)[J]. Gastroenterology, 2022, 162( 3): 757- 771. e 4. DOI: 10.1053/j.gastro.2021.11.002.
[37]	LIM SG, TEO AE, CHAN ESY, et al. Stopping nucleos(t)ide analogues in chronic hepatitis B using HBsAg thresholds: A meta-analysis and meta-regression[J]. Clin Gastroenterol Hepatol, 2024, 22( 12): 2403- 2412. DOI: 10.1016/j.cgh.2024.05.040.
[38]	BEUDEKER BJB, OSMANI Z, van OORD GW, et al. Association of HBsAg levels with differential gene expression in NK CD8 T, and memory B cells in treated patients with chronic HBV[J]. JHEP Rep, 2023, 6( 2): 100980. DOI: 10.1016/j.jhepr.2023.100980.
[39]	VERHEIJDEN S, TUEFFERD M, CRABBE M, et al. WED-372 Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients[J]. J Hepatol, 2024, 80: S810. DOI: 10.1016/S0168-8278(24)02237-2.
[40]	HOGAN T, CASTANEDA EG, GARCIA EP, et al. WED-364 High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naïve B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8⁺ T cells in responders versus nonresponders to bepirovirsen[J]. J Hepatol, 2024, 80: S807. DOI: 10.1016/S0168-8278(24)02231-1.
[41]	BERG T, SIMON KG, MAUSS S, et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients-FINITE study[J]. J Hepatol, 2017, 67( 5): 918- 924. DOI: 10.1016/j.jhep.2017.07.012.
[42]	HOU J, XIE Q, ZHANG W. Outcomes of nucleos(t)ide analogue discontinuation in chronic hepatitis B participants treated with xalnesiran with and without an immunomodulator: 48 weeks of follow-up results from the phase 2, randomized, controlled, adaptive, open-label platform study piranga[J]. AASLD the Liver Meeting, 2024, Abstract 252.

Relative Articles

[1]	Xiaoqi YU, Xinxin ZHANG. Effect of hepatitis B virus integration on functional cure[J]. Journal of Clinical Hepatology, 2025, 41(1): 24-29. doi: 10.12449/JCH250104
[2]	Hui ZHUANG. Functional cure of chronic hepatitis B is not a dream[J]. Journal of Clinical Hepatology, 2025, 41(1): 2-6. doi: 10.12449/JCH250101
[3]	Na GAO, Zhiliang GAO. How far is the functional cure of chronic hepatitis B from complete cure?[J]. Journal of Clinical Hepatology, 2025, 41(1): 15-23. doi: 10.12449/JCH250103
[4]	Journal of Hepatology｜Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy[J]. Journal of Clinical Hepatology, 2024, 40(11): 2237-2237. doi: 10.12449/JCH2411.gwqkjpwzjj2
[5]	Kuan LI, Huibin NING, Huiming JIN, Zhen PENG, Jia SHANG. Effect of pegylated interferon α-2b on serum HBsAg clearance rate in treatment of patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(8): 1819-1824. doi: 10.3969/j.issn.1001-5256.2023.08.009
[6]	Haiyang ZANG, Weina LI, Shousheng LIU, Yong ZHOU, Yongning XIN. Predictive factors for functional cure after sequential therapy with nucleos(t)ide analogues and pegylated interferon alfa-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(2): 299-306. doi: 10.3969/j.issn.1001-5256.2023.02.008
[7]	Caijun HAN, Yuan HUANG, Bin NIAN, Meihua PIAO. Value of von Willebrand factor antigen-to-albumin ratio and glycocalicin index in predicting esophageal varices in hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(12): 2750-2754. doi: 10.3969/j.issn.1001-5256.2022.12.013
[8]	Juan CHEN, Ailong HUANG. Functional cure of hepatitis B from the perspective of hepatitis B virus covalently closed circular DNA[J]. Journal of Clinical Hepatology, 2022, 38(8): 1716-1720. doi: 10.3969/j.issn.1001-5256.2022.08.003
[9]	Yifei GUO, Jiming ZHANG. Influencing factors for the functional cure of chronic hepatitis B and related mechanism[J]. Journal of Clinical Hepatology, 2022, 38(8): 1721-1725. doi: 10.3969/j.issn.1001-5256.2022.08.004
[10]	Cheng Na, Yang Jing. Association of estrogen receptor α gene polymorphisms with hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 186-189. doi: 10.3969/j.issn.1001-5256.2020.01.044
[11]	Chen Xi, Zhao WenJing, Sun Yan, Yin HaiYan. Value of baseline HBsAg quantification in predicting the clinical effect of pegylated interferon α-2b in treatment of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(8): 1723-1726. doi: 10.3969/j.issn.1001-5256.2020.08.009
[12]	Zheng Xin, Liu Jia, Wu Jun, Meng ZhongJi, Lu MengJi, Yang DongLiang. Advances and challenges in immune control and functional cure of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2020, 36(5): 961-964. doi: 10.3969/j.issn.1001-5256.2020.05.001
[13]	Chen JieLiang, Yuan ZhengHong. Influence of interferon and nucleos (t) ide analogues on HBV cccDNA and functional cure of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(6): 1181-1187. doi: 10.3969/j.issn.1001-5256.2019.06.002
[14]	Zhou YouQian, Li Cui, Yin FengMing, Zhang HaiYan, Ren Bin, Yang Wei. Change in HBsAg quantification after HBV DNA negative conversion in chronic hepatitis B patients treated with nucleos (t) ide analogues[J]. Journal of Clinical Hepatology, 2019, 35(5): 977-981. doi: 10.3969/j.issn.1001-5256.2019.05.009
[15]	Chinese Society of Infectious Disease, Chinese Society of Hepatology, Chinese Medical Association. The expert consensus on clinical cure (functional cure) of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2019, 35(8): 1693-1701. doi: 10.3969/j.issn.1001-5256.2019.08.008
[18]	Yu YongSheng, Zang GuoQing, Pan YuQing. The role of infiltrating lymphocytes' LFA-1 expression in hepatic cell injury and HBV clearance within liver with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2003, 19(3): 171-173.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (381) PDF downloads(131)

New drugs for the functional cure of hepatitis B: Focusing on antisense oligonucleotides and small interfering RNAs

DOI: 10.12449/JCH250102

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

New drugs for the functional cure of hepatitis B: Focusing on antisense oligonucleotides and small interfering RNAs

DOI: 10.12449/JCH250102

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content